Akero Therapeutics

📍 South San Francisco, United States🗓 Founded 2017👥 53 employees💰 Last funded Jun 2018
Biotechnology Research🌐 akerotx.com
Website LinkedIn
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Akero Therapeutics?
Akero Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Akero Therapeutics last raise funding?
The most recent investment in Akero Therapeutics recorded on gritt.io was in June 2018.
When was Akero Therapeutics founded?
Akero Therapeutics was founded in 2017.
What industry is Akero Therapeutics in?
Akero Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Akero Therapeutics based?
Akero Therapeutics is headquartered in South San Francisco, United States.